The specification relates to compounds of Formula (I)： and pharmaceutically acceptable salts thereof, where Q, R, R1 and R2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent GLS1 mediated disease, including cancer. The specification further relates to crystalline forms of compounds of Formula (I) and pharmaceutically acceptable salts thereof； pharmaceutical compositions comprising such compounds and salts； kits comprising such compounds and salts； methods of manufacture of such compounds and salts； intermediates useful in the manufacture of such compounds and salts； and to methods of treating GLS1 kinase mediated disease, including cancer, using such compounds and salts.本說明書係關於式(I)化合物：及其醫藥學上可接受之鹽，其中Q、R、R1及R2具有本文所定義之意義中之任一者。本說明書亦關於此類化合物及其鹽於治療或預防包括癌症之GLS1介導之疾病的用途。本說明書進一步關於式(I)化合物及其醫藥學上可接受之鹽之結晶形式；包含此類化合物及鹽之醫藥組合物；包含此類化合物及鹽之套組；製造此類化合物及鹽之方法；適用於製造此類化合物及鹽之中間物；及使用此類化合物及鹽治療包括癌症之GLS1激酶介導之疾病的方法。
